Rockefeller Capital Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Rockefeller Capital Management's NRIX Position: Q3 2026 in Review
Rockefeller Capital Management increased its Nurix Therapeutics (NRIX) stake by 0.24% in Q3 2026, buying an estimated $324 and bringing the position to 5,331 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #2928.
Rockefeller Capital Management first reported a position in NRIX in Q2 2022 and has held it in 7 quarters since. The position peaked at $129K in Q2 2026. 233 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Rockefeller Capital Management held 5,331 shares of Nurix Therapeutics worth $126K as of Q3 2026.
- Rockefeller Capital Management bought 13 Nurix Therapeutics shares in Q3 2026, an estimated $324.
- Nurix Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #2928 holding.
- Rockefeller Capital Management first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 7 quarters since.
- Rockefeller Capital Management's Nurix Therapeutics position peaked at $129K in Q2 2026.
- 233 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.